Despite the uniform confirmation of AT1R blockade (ARB)-mediated memory improvement and anti-inflammatory effects in AD models, the impact of this drug class on amyloid (Aβ) plaque pathology remains controversial. This evidence concerns the gene AGTR1 and Alzheimer disease.